Journal
ONCOIMMUNOLOGY
Volume 4, Issue 5, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1005504
Keywords
CD8(+) T cell; dendritic cell; fusokine; immunotherapy; intratumoral; IFN beta; mRNA; TGF beta receptor II
Categories
Funding
- Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy
- National Cancer Plan of the Federal Ministry of Health
- Stichting tegen Kanker
- Vlaamse Liga tegen Kanker
- FWO-Vlaanderen
- Scientific Fund Willy Gepts of the University Hospital Brussels
- Vrije Universiteit Brussel
- IWT-TBM program
- EU FP7
Ask authors/readers for more resources
The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine F-2 supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
